Cargando…

Effectiveness of Vitamin D Supplementation in the Management of Multiple Sclerosis: A Systematic Review

Objective: to examine the extent of effect vitamin D in Multiple Sclerosis (MS) on pathology and symptoms. Methods: A literature search was performed in November 2018 (CRD42018103615). Eligibility criteria: randomised control trials in English from 2012 to 2018; a clinical diagnosis of MS; intervent...

Descripción completa

Detalles Bibliográficos
Autores principales: Berezowska, Monika, Coe, Shelly, Dawes, Helen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6471017/
https://www.ncbi.nlm.nih.gov/pubmed/30875858
http://dx.doi.org/10.3390/ijms20061301
_version_ 1783411929714262016
author Berezowska, Monika
Coe, Shelly
Dawes, Helen
author_facet Berezowska, Monika
Coe, Shelly
Dawes, Helen
author_sort Berezowska, Monika
collection PubMed
description Objective: to examine the extent of effect vitamin D in Multiple Sclerosis (MS) on pathology and symptoms. Methods: A literature search was performed in November 2018 (CRD42018103615). Eligibility criteria: randomised control trials in English from 2012 to 2018; a clinical diagnosis of MS; interventions containing vitamin D supplementation (vitamin D3 or calcitriol) in disease activity compared to a control/placebo; improvement in: serum 25(OH)D, relapse rates, disability status by Expanded Disability Status Scale (EDSS) scores, cytokine profile, quality of life, mobility, T2 lesion load and new T2 or T1 Gd enhancing lesions, safety and adverse effects. Risk of bias was evaluated. Results: Ten studies were selected. The study size ranged from 40 to 94 people. All studies evaluated the use of vitamin D supplementation (ranging from 10 to 98,000 IU), comparing to a placebo or low dose vitamin D. The duration of the intervention ranged from 12 to 96 weeks. One trial found a significant effect on EDSS score, three demonstrated a significant change in serum cytokines level, one found benefits to current enhancing lesions and three studies evaluating the safety and tolerability of vitamin D reported no serious adverse events. Disease measures improved to a greater extent overall in those with lower baseline serum 25(OH)D levels. Conclusions: As shown in 3 out of 10 studies, improvement in disease measures may be more apparent in those with lower baseline vitamin D levels.
format Online
Article
Text
id pubmed-6471017
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-64710172019-04-26 Effectiveness of Vitamin D Supplementation in the Management of Multiple Sclerosis: A Systematic Review Berezowska, Monika Coe, Shelly Dawes, Helen Int J Mol Sci Review Objective: to examine the extent of effect vitamin D in Multiple Sclerosis (MS) on pathology and symptoms. Methods: A literature search was performed in November 2018 (CRD42018103615). Eligibility criteria: randomised control trials in English from 2012 to 2018; a clinical diagnosis of MS; interventions containing vitamin D supplementation (vitamin D3 or calcitriol) in disease activity compared to a control/placebo; improvement in: serum 25(OH)D, relapse rates, disability status by Expanded Disability Status Scale (EDSS) scores, cytokine profile, quality of life, mobility, T2 lesion load and new T2 or T1 Gd enhancing lesions, safety and adverse effects. Risk of bias was evaluated. Results: Ten studies were selected. The study size ranged from 40 to 94 people. All studies evaluated the use of vitamin D supplementation (ranging from 10 to 98,000 IU), comparing to a placebo or low dose vitamin D. The duration of the intervention ranged from 12 to 96 weeks. One trial found a significant effect on EDSS score, three demonstrated a significant change in serum cytokines level, one found benefits to current enhancing lesions and three studies evaluating the safety and tolerability of vitamin D reported no serious adverse events. Disease measures improved to a greater extent overall in those with lower baseline serum 25(OH)D levels. Conclusions: As shown in 3 out of 10 studies, improvement in disease measures may be more apparent in those with lower baseline vitamin D levels. MDPI 2019-03-14 /pmc/articles/PMC6471017/ /pubmed/30875858 http://dx.doi.org/10.3390/ijms20061301 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Berezowska, Monika
Coe, Shelly
Dawes, Helen
Effectiveness of Vitamin D Supplementation in the Management of Multiple Sclerosis: A Systematic Review
title Effectiveness of Vitamin D Supplementation in the Management of Multiple Sclerosis: A Systematic Review
title_full Effectiveness of Vitamin D Supplementation in the Management of Multiple Sclerosis: A Systematic Review
title_fullStr Effectiveness of Vitamin D Supplementation in the Management of Multiple Sclerosis: A Systematic Review
title_full_unstemmed Effectiveness of Vitamin D Supplementation in the Management of Multiple Sclerosis: A Systematic Review
title_short Effectiveness of Vitamin D Supplementation in the Management of Multiple Sclerosis: A Systematic Review
title_sort effectiveness of vitamin d supplementation in the management of multiple sclerosis: a systematic review
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6471017/
https://www.ncbi.nlm.nih.gov/pubmed/30875858
http://dx.doi.org/10.3390/ijms20061301
work_keys_str_mv AT berezowskamonika effectivenessofvitamindsupplementationinthemanagementofmultiplesclerosisasystematicreview
AT coeshelly effectivenessofvitamindsupplementationinthemanagementofmultiplesclerosisasystematicreview
AT daweshelen effectivenessofvitamindsupplementationinthemanagementofmultiplesclerosisasystematicreview